Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board

BOSTON, MASSACHUSETTS, July 31, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that it named Leslie Ajayi, MD as its interim Chief Medical Officer and Chief of the Medical Advisory Board. In this role Dr. Ajay will provide leadership and direction to the clinical operations, clinical affairs, clinical sciences, and drug safety. He will report to the CEO Dr David Platt and chair the Medical Advisory Board.

Dr. Ajayi brings over 20 years of clinical development experience in academia and industry. He is a fully trained physician leader with international specialty training in internal medicine, cardiovascular medicine, and clinical pharmacology. He received his undergraduate training in Health Sciences and his MD equivalent graduating Magna Cum Lade from Obafemi Awolowo University [OAU] in Nigeria. A few years later he received his PhD in clinical pharmacology from the University of Glasgow. As an academic clinical pharmacologist in Glasgow, UK, he worked with Big Pharma as an investigator for Phase 1 first in man, proof of concept, pharmacokinetics (PK), Pharmacodynamics (PD), PK-PD, and studies in special populations such as the elderly and in pregnancy. He was also involved in all types of designs of randomized controlled clinical trials (double blind, placebo controlled, double dummy, single blind, cross over, parallel group, Latin squares designs). His industry exposure was relegated to big pharma clinical research monitors and clinical research organizations. He worked on notable projects like perindopril and cilazapril (ACEI), and amlodipine. He evaluated the effects of ACEI on Type-2 Diabetes and insulin resistance in hypertensives.

During his tenure at OAU he served in a number of leadership positions. He was the vice dean of Clinical Sciences at OAU. Eventually he became the chairman of medicine at OAU and the chairman of hospital drug formulator committee at OAU. He also has held a number of Academic and Research roles. Some of his more notable roles were as an adjunct professor of medicine at Baylor College. He was also a professor of pharmacology for Sava University School of Medicine, St James School of Medicine, and Ross University.